Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly Resubmits Cymbalta Supplemental New Drug Application To FDA
Eli Lilly has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain, to the FDA. The resubmission is based on
Eli Lilly has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain, to the FDA. The resubmission is based on
Genta has declared preliminary results showing a high objective response rate and potentially extended survival in an ongoing pilot study. The trial incorporates the company’s lead oncology product,
NPS Pharmaceuticals has presented new data from three sub-studies in patients with short bowel syndrome (SBS) who received Gattex (teduglutide) during a 24-week, placebo-controlled Phase 3 clinical trial.
Nabi has received scientific advice from the European Medicines Agency (EMEA) on Nicvax, regarding the requirements for marketing authorization submission, as it relates to the appropriate design of
Net sales attributable to the epilepsy indication of $140 million compared to $115.3 million in fiscal year 2008, a 21% increase; Gross margin of 86.0%, compared with 82.6%
Opportunities abound for overseas players like major US teaching institutions. Meanwhile, the Gulf states are also struggling with a system of health care reform. According to FT, the
As well as being a great place to work for 400 employees, chief executive officer of Coloplast Lars Rasmussen believes the new building underscores Coloplast’s ambitions in the
Vical has received US Patent No. 7537768, covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as
CombiMatrix has announced that the validation study performed by its wholly-owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), in collaboration with the Department of Pathology at the University of Texas
Dr. John Padfield, Optos’ chairman said: On behalf of the Board I would like to thank Allan for the excellent contribution he has made to the business. Since